Results of the phase 1/2 ZUMA-3 trial of Tecartus (brexucabtagene autoleucel) reported at the ongoing ASCO conference revealed a 71% complete response rate with the CAR-T in heavily pre-treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback